Intended for healthcare professionals

News

Esketamine for treatment resistant depression is not recommended by NICE

BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m329 (Published 28 January 2020) Cite this as: BMJ 2020;368:m329

Linked Editorial

Esketamine for treatment resistant depression

  1. Elisabeth Mahase
  1. The BMJ

An esketamine nasal spray may not be made available on the NHS for patients with treatment resistant depression because of uncertainties over its clinical and cost effectiveness, says draft guidance from the National Institute for Health and Care Excellence.1

NICE reviewed the effectiveness of esketamine in combination with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor for adults with treatment resistant depression that have not responded to at least two different antidepressants in the current moderate to severe depressive episode.

It said that …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription